NCT05366283View on ClinicalTrials.gov

Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by Inhalation

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

May 27, 2022

Study Completion Date

June 16, 2022

Conditions
Drug KineticsDrug Effects on Physiology
Interventions
BIOLOGICAL

sargramostim

Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor.

Trial Locations (1)

H3P 3P1

AltaSciences, Mount Royal

Sponsors
All Listed Sponsors
lead

Partner Therapeutics, Inc.

INDUSTRY